See you tomorrow at #ASGCT23! We’re excited to share new data from our lead program targeting 𝘈𝘉𝘊𝘈4 retinopathies.

At 9am PT, #TeamAscidian’s Head of Research will present on how we’re #RewritingRNA for the treatment of #Stargardt disease.
👉 https://bit.ly/3MBG592

Look out 👀 for Ascidian & new data on its lead program targeting ABCA4 retinopathies, including #Stargardt disease, at the 2023 Retinal Cell & Gene Therapy Innovation Summit & #ARVO2023 meeting.

Learn more 👉 https://ascidian-tx.com/press-releases/

In support of #RareDiseaseDay, we’re sharing three things to know about #Stargardt disease and our work to #RewriteRNA for people affected by this genetically inherited eye disorder. Thanks to Tayla Cormier for sharing your passion and expertise! 👇

https://www.linkedin.com/posts/ascidian-therapeutics_rarediseaseday-stargardt-rewriterna-activity-7036333963602231296-d7j5?utm_source=share&utm_medium=member_desktop